At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Envarsus XRdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus
In Brief
A Phase 4 clinical trial evaluating Envarsus XR for Renal Transplant Patients. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a pilot study documenting the neurotoxic side effects including tremors in patients with a stable graft who are receiving Tacrolimus following kidney transplantation. A standardized questionnaire will be used to document these symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant Patients
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartDec 2017
Primary CompletionMay 2020
Study CompletionJun 2020
TodayJul 2026
First PostedSep 1, 2017
Enrollment StartDec 1, 2017
Primary CompletionMay 2, 2020
Study CompletionJun 2, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.8 years ago
Interventions
Envarsus XRdrug
Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.